Billets de Michelle Dawson

Billet publié sur Twitter/X le 18/04/2022 12:16

Twitter/X Publication avec DOI crossref Question posée par Dawson dans le billet Lien intégré au billet Termes sur l’autisme

Liens cités structurés

1 ressource citée

Publication avec DOI Récupéré Publication crossref

Q. Liu, W. Yin, J.J. Meijsen, A. Reichenberg, J.R. Gådin, A.J. Schork, H.-O. Adami, A. Kolevzon, et al. (2022). Cancer risk in individuals with autism spectrum disorder. Annals of Oncology, 33(7), 713-719. Elsevier BV.

Date de publication
juillet 2022
Identifiant
10.1016/j.annonc.2022.04.006
Auteurs
Q. Liu, W. Yin, J.J. Meijsen, A. Reichenberg, J.R. Gådin, A.J. Schork, H.-O. Adami, A. Kolevzon, S. Sandin, F. Fang
Source
Annals of Oncology
Détails
33(7), 713-719
Type de référence
article
Éditeur
Elsevier BV
Source de métadonnées
crossref

Résumé

BACKGROUND: Whether individuals with autism spectrum disorders (ASDs) have a higher-than-expected risk of cancer remains unknown. PATIENTS AND METHODS: We carried out a population-based cohort study including 2.3 million individuals live-born to mothers from Nordic countries during 1987-2013 in Sweden with follow-up through 2016 (up to age 30 years). Individuals with ASD were ascertained through the Swedish National Patient Register. We estimated the relative risk of cancer in relation to ASD by odds ratios (ORs) and associated 95% confidence intervals (CIs) derived from logistic regression, after detailed adjustment for potential confounders. We also carried out a sibling comparison to address familial confounding and a genetic correlation analysis using the genome-wide association study summary statistics to address confounding due to potential polygenetic pleiotropy between ASD and cancer. RESULTS: We observed an overall increased risk of any cancer among individuals with ASD (OR 1.3, 95% CI 1.2-1.5), compared with individuals without ASD. The association for any cancer was primarily noted for narrowly defined autistic disorder (OR 1.7, 95% CI 1.3-2.1) and ASD with comorbid birth defects (OR 2.1, 95% CI 1.5-2.9) or both birth defects and intellectual disability (ID; OR 4.8, 95% CI 3.4-6.6). An association was also suggested for ASD with comorbid ID (OR 1.4; 95% CI 0.9-2.1), but was not statistically significant. ASD alone (i.e. without comorbid ID or birth defects) was not associated with an increased risk of any cancer (OR 1.0, 95% CI 0.8-1.2). Sibling comparison and genetic correlation analysis showed little evidence for familial confounding or confounding due to polygenetic pleiotropy between ASD and cancer. CONCLUSIONS: ASD per se is not associated with an increased risk for cancer in early life. The increased cancer risk among individuals with ASD is likely mainly attributable to co-occurring ID and/or birth defects in ASD.

Auteur·ices de l’étude dans cette référence citée